AstraZeneca vaccine faces another setback after independent board questions trial data

The coronavirus vaccine developed by AstraZeneca is facing yet another setback.
On Tuesday, an independent review board of experts appointed by the National Institutes of Health said the British-Swedish pharmaceutical company may have only used partial data when it announced the results from its vaccine trial. The unusual rebuke from health officials follows a series of missteps and false starts in AstraZeneca’s rollout of the vaccine.
Anthony S. Fauci, director of the NIH’s National Institute of Allergy and Infectious Diseases, called the concerns raised by the board an “unforced error” on AstraZeneca’s part, saying the shot “is very likely a good vaccine.” The company said it would “immediately engage” with health officials to discuss the most up-to-date efficacy data and promised a more detailed analysis within 48 hours of the vaccine it developed with Oxford University.